Astraveus

Astraveus is a pioneering biotechnology company based in the Paris region, dedicated to revolutionizing the manufacturing of cell and gene therapies (CGTs). By developing advanced, automated, and microfluidic-based systems, the company aims to overcome the significant cost, complexity, and scalability barriers that currently limit patient access to life-changing treatments. Their flagship platform, Lakhesys™, serves as a benchtop cell factory that integrates hardware, software, and single-use consumables to streamline production from clinical research to commercial scale. Founded in 2016 by Dr. Jérémie Laurent, Astraveus emerged from research at the Saint-Louis Hospital with the vision of treating biological processes with the precision of computing. The company has gained significant industry traction, recently achieving the first successful end-to-end production of CAR-T cells using its proprietary microfluidic technology. Supported by major investors including M Ventures and Johnson & Johnson Innovation, Astraveus is currently scaling its operations to transform the industrial landscape of biotechnology.

Astraveus strives to enable a healthier tomorrow by revolutionizing the development and manufacturing of cell and gene therapies, making these treatments more accessible to the largest possible number of patients.

• Achieved world-first end-to-end production of CAR-T cells using microfluidic benchtop technology in 2025
• Secured strategic partnership with CDMO NecstGen to evaluate Lakhesys platform capabilities
• Recipient of significant funding from major life science investors and French government grants via France 2030
• Successfully transitioned from stealth mode to commercialization phase with key leadership appointments

Sources

• Astraveus Official Website
• PR Newswire
• LaBiotech.eu